A Systematic Pan-Cancer Analysis of MEIS1 in Human Tumors as Prognostic Biomarker and Immunotherapy Target

Han, Lei; Tang, Ying; Hua, Lichun; Wang, Zemin; Du, Guizhi; Wang, Shuai; Lu, Shi-Feng; Li, Wei

doi:10.3390/jcm12041646

Cited by 3 publications

(2 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FGSEA analysis further proves that MEIS1 co-expressed with cell cycle, DNA repair, and DNA metabolic process genes. A study revealed a high correlation between MEIS1 expression and the majority of immune cells in various cancers (Li et al 2023 ). For example, the FTO/RP5-991G20.1/hsa-miR-1976/MEIS1 regulatory axis is necessary for regulating the infiltration of immune cells and prognosis in ovarian cancer patients (Chen et al 2023 ).…”

Section: Discussionmentioning

confidence: 99%

The impact of MEIS1 TALE homeodomain transcription factor knockdown on glioma stem cell growth

Kim,

Batara,

Jeon

et al. 2024

Animal Cells and Systems

View full text Add to dashboard Cite

Myeloid ecotropic virus insertion site 1 ( MEIS1 ) is a HOX co-factor necessary for organ development and normal hematopoiesis. Recently, MEIS1 has been linked to the development and progression of various cancers. However, its role in gliomagenesis particularly on glioma stem cells (GSCs) remains unclear. Here, we demonstrate that MEIS1 is highly upregulated in GSCs compared to normal, and glioma cells and to its differentiated counterparts. Inhibition of MEIS1 expression by shRNA significantly reduced GSC growth in both in vitro and in vivo experiments. On the other hand, integrated transcriptomics analyses of glioma datasets revealed that MEIS1 expression is correlated to cell cycle-related genes. Clinical data analysis revealed that MEIS1 expression is elevated in high-grade gliomas, and patients with high MEIS1 levels have poorer overall survival outcomes. The findings suggest that MEIS1 is a prognostic biomarker for glioma patients and a possible target for developing novel therapeutic strategies against GBM.

show abstract

Section: Discussionmentioning

confidence: 99%

The impact of MEIS1 TALE homeodomain transcription factor knockdown on glioma stem cell growth

Kim,

Batara,

Jeon

et al. 2024

Animal Cells and Systems

View full text Add to dashboard Cite

show abstract

“…Breast cancer overlook lung cancer as the most frequently diagnosed cancer worldwide in 2020, accounting for nearly 12% of new cases [ 1 ]. Breast cancer cells show metabolic abnormalities and mitochondrial oxidative stress, and various tumor marker proteins are increased [ 2 , 3 , 4 ]. A combination of preoperative chemotherapy and surgery is the current treatment strategy for breast cancer patients.…”

Section: Introductionmentioning

confidence: 99%

Ribosome Biogenesis Regulator 1 Homolog (RRS1) Promotes Cisplatin Resistance by Regulating AEG-1 Abundance in Breast Cancer Cells

Song

Peng²,

Wang

et al. 2023

Molecules

View full text Add to dashboard Cite

Many ribosomal proteins are highly expressed in tumors and are closely related to their diagnosis, prognosis and pathological characteristics. However, few studies are available on the correlation between ribosomal proteins and chemoresistance. RRS1 (human regulator of ribosome synthesis 1), a critical nuclear protein involved in ribosome biogenesis, also plays a key role in the genesis and development of breast cancer by protecting cancer cells from apoptosis. Given that apoptosis resistance is one of the causes of the cisplatin resistance of tumor cells, our aim was to determine the relationship between RRS1 and cisplatin resistance in breast cancer cells. Here, we report that RRS1 is associated with cisplatin resistance in breast cancer cells. RRS1 silencing increased the sensitivity of MCF-7/DDP cells to cisplatin and inhibited cancer cell proliferation by blocking cell cycle distribution and enhancing apoptosis. AEG-1 (astrocyte elevated gene-1) promotes drug resistance by interfering with the ubiquitination and proteasomal degradation of MDR1 (multidrug resistance gene 1), thereby enhancing drug efflux. We found that RRS1 binds to and stabilizes AEG-1 by inhibiting ubiquitination and subsequent proteasomal degradation, which then promotes drug efflux by upregulating MDR1. Furthermore, RRS1 also induces apoptosis resistance in breast cancer cells through the ERK/Bcl-2/BAX signaling pathway. Our study is the first to show that RRS1 sensitizes breast cancer cells to cisplatin by binding to AEG-1, and it provides a theoretical basis to improve the efficacy of cisplatin-based chemotherapy.

show abstract

The Roles of H3K9me3 Writers, Readers, and Erasers in Cancer Immunotherapy

Oleksiewicz,

Kuciak,

Jaworska

et al. 2024

IJMS

View full text Add to dashboard Cite

The interplay between cancer and the immune system has captivated researchers for a long time. Recent developments in cancer immunotherapy have substantiated this interest with a significant benefit to cancer patients. Tumor and immune cells are regulated via a wide range of molecular mechanisms involving intricate transcriptional and epigenetic networks. Epigenetic processes influence chromatin structure and accessibility, thus governing gene expression, replication, and DNA damage repair. However, aberrations within epigenetic signatures are frequently observed in cancer. One of the key epigenetic marks is the trimethylation of histone 3 at lysine 9 (H3K9me3), confined mainly within constitutive heterochromatin to suppress DNA accessibility. It is deposited at repetitive elements, centromeric and telomeric loci, as well as at the promoters of various genes. Dysregulated H3K9me3 deposition disrupts multiple pathways, including immune signaling. Consequently, altered H3K9me3 dynamics may modify the efficacy of immunotherapy. Indeed, growing evidence highlights the pivotal roles of various proteins mediating H3K9me3 deposition (SETDB1/2, SUV39H1/2), erasure (KDM3, KDM4 families, KDM7B, LSD1) and interpretation (HP1 proteins, KAP1, CHD4, CDYL, UHRF1) in modulating immunotherapy effectiveness. Here, we review the existing literature to synthesize the available information on the influence of these H3K9me3 writers, erasers, and readers on the response to immunotherapy.

show abstract

A Systematic Pan-Cancer Analysis of MEIS1 in Human Tumors as Prognostic Biomarker and Immunotherapy Target

Cited by 3 publications

References 51 publications

The impact of MEIS1 TALE homeodomain transcription factor knockdown on glioma stem cell growth

The impact of MEIS1 TALE homeodomain transcription factor knockdown on glioma stem cell growth

Ribosome Biogenesis Regulator 1 Homolog (RRS1) Promotes Cisplatin Resistance by Regulating AEG-1 Abundance in Breast Cancer Cells

The Roles of H3K9me3 Writers, Readers, and Erasers in Cancer Immunotherapy

Contact Info

Product

Resources

About